Tris Pharma

70 articles with Tris Pharma

• Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

  2/22/2021

   Tris Pharma, Inc. ("Tris") and Athena Bioscience LLC ("Athena") announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris' proprietary technology.

• Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting

  1/15/2021

  Tris Pharma, Inc. announced that it will present pivotal efficacy and safety data on its new amphetamine extended-release tablet at the virtual annual meeting of American Professional Society of ADHD and Related Disorders to be held from Friday, January 15 through Sunday, January 17, 2021.

• Tris Pharma Hires Seasoned Research & Development Executive

  12/18/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder

• Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris' Quillivant XR and Quillichew ER in Europe

  12/8/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group ("Neuraxpharm"), a leading European specialty pharma

• Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel

  11/17/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma ("Medison"), a leading international commercial partner for highly innovat

• Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers

  11/10/2020

  Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new website for patients and their caregivers.

• Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the Research Pipeline Session of 2020 American Academy of Child and Adolescent Psychiatry Meeting

  10/22/2020

   Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Amy Everitt , MS, PharmD of Tris' Medical team wi

• Tris Pharma Launches its Scientific Advisory Board

  10/6/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific Advi

• Tris Pharma Launches Redesigned Website for ADHD Healthcare Professionals

  9/17/2020

  Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced today the launch of a redesigned website for healthcare professionals (HCPs).  This newly redesigned

• Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

  7/9/2020

   Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario a

• Tris Pharma Launches New Corporate Website

  6/25/2020

  Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new corporate website that better embodies the company's evolving business model and strategic goals.

• Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic

  3/17/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, amidst the uncertainty created by the COVID-19 pandemic, reiterated its commitment to the ADHD community by assuring ADHD pat

• Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team

  10/30/2019

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Jonathan N. Provoost has joined the company as General Counsel, overseeing all of its legal functions.

• Tris Pharma Strengthens Its Branded Commercial Leadership Team

  9/4/2019

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the addition of two industry veterans to join its growing branded business

• Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee

  8/14/2019

  Tris Pharma, Inc. ("Tris"), is announcing that its Chief Medical Officer, Barry K. Herman, M.D., M.M.M. has been elected to the American Psychiatric Association (APA) Assembly Executive Committee. 

• Tris Pharma, Inc. Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

  1/29/2019

  Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3) additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, to the retail (pharmacy) level.

• Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris' LiquiXR® Technology at the 2019 APSARD Annual Meeting

  1/17/2019

  Tris Pharma, Inc., announced that it will present information on its proprietary drug delivery platform LiquiXR® as well as data from two clinical studies on DYANAVEL XR (amphetamine) extended-release oral suspension, CII, at the 2019 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting held in Washington, D.C., January 18 to January 20, 2019.

• Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

  11/12/2018

  The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1 hour and a duration of effect up to 13 hours after dosing

• Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists

  10/24/2018

  65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) taking place in Seattle, Washington, October 22 to 27, 2018.

• Tris Pharma Announces Hiring of Chief Commercial Officer

  10/10/2018

  Tris Pharma, Inc. today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris' expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.